At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Open-label Placeboother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Harnessing the Placebo Effect in Major Depressive Disorder
In Brief
A Phase 2 clinical trial evaluating Open-label Placebo for Major Depressive Disorder. Completed, enrolled 20 participants across 1 site.
Detailed Summary
Placebo pills (pills with no active ingredients) have been shown in research studies to somehow produce self-healing processes. The purpose of this study is to determine whether people will be willing to enter an open-label non-deceptive placebo treatment for Major Depressive Disorder (MDD) and whether open-label placebo can be effective for treating MDD in the context of a supportive physician-patient relationship.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2010
Enrollment StartMay 2010
Primary CompletionMay 2011
TodayJul 2026
First PostedApr 14, 2010
Enrollment StartMay 1, 2010
Primary CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 16.2 years ago
Interventions
Open-label Placeboother
Participants take open-label placebo pills - two twice daily for four weeks.